Singapore markets open in 28 minutes

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
26.80-0.30 (-1.11%)
At close: 04:00PM EST
26.80 0.00 (0.00%)
After hours: 06:13PM EST
Full screen
Trade prices are not sourced from all markets
Previous close27.10
Open27.11
Bid26.81 x 800
Ask26.78 x 800
Day's range26.50 - 27.37
52-week range19.80 - 29.23
Volume634,728
Avg. volume704,478
Market cap1.506B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

    – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition – – Two Additional Phase 3 Readouts of Mitapivat Expected in 2024, with a Total of Four Phase 3 Readouts by the End of 2025 – – U.S. PYRUKYND® (mitapivat) Net Revenue of $7.1 Million in Q4; Cash, Cash Equivalents

  • GlobeNewswire

    Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

    CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report its fourth quarter and year end 2023 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors sec

  • GlobeNewswire

    Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

    – Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia – – Company Expects Four Additional Phase 3 Readouts by the End of 2025, with Potential FDA Approvals in Thalassemia in 2025 and Sickle Cell Disease in 2026 – – Strong Cash Position Expected to Support Completion of Ongoing Programs and Disciplined Pipeline Expansion at Least into 2026 – CAMBRIDGE, Mass., Jan. 08